Trial · NCT00348881
Results by group118
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 118
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Hep Bs (N = 246, 122) | 239 | Participants | |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Hep Bs (N = 246, 122) | 119 | 0 to 0 | Participants |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-PRP (N = 218, 122) | 210 | Participants | |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-PRP (N = 218, 122) | 121 | 0 to 0 | Participants |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Diphtheria (N = 246, 123) | 217 | Participants | |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Diphtheria (N = 246, 123) | 109 | 0 to 0 | Participants |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP~T + OPV | Anti-Tetanus (N = 246,123) | 246 | Participants | |
Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies After Vaccination With Either DTaP-Hep B-PRP~T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Tetanus (N = 246,123) | 123 | 0 to 0 | Participants |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP-T + OPV | Anti-Hep Bs (N = 246, 122) | 464 | 95% Confidence Interval 380 to 567 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Hep Bs (N = 246, 122) | 343 | 95% Confidence Interval 265 to 444 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP-T + OPV | Anti-PRP (N = 218, 121) | 3.02 | 95% Confidence Interval 2.47 to 3.69 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-PRP (N = 218, 121) | 10.3 | 95% Confidence Interval 8.30 to 12.8 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP-T + OPV | Anti-Diphtheria (N = 246, 123) | 0.025 | 95% Confidence Interval 0.022 to 0.028 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Diphtheria (N = 246, 123) | 0.023 | 95% Confidence Interval 0.019 to 0.028 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP-T + OPV | Anti-Tetanus (N = 246, 123) | 1.05 | 95% Confidence Interval 0.958 to 1.14 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Tetanus (N = 246, 123) | 1.31 | 95% Confidence Interval 1.14 to 1.49 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP-T + OPV | Anti-Pertusiss (N = 245, 108) | 139 | 95% Confidence Interval 127 to 152 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Pertusiss (N = 245, 108) | 81.5 | 95% Confidence Interval 57.3 to 116 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 1: DTaP-Hep B-PRP-T + OPV | Anti-Filamentous Hemagglutinin (N = 205, 94) | 86.7 | 95% Confidence Interval 80.0 to 93.9 | Titers |
| Geometric Mean Titers (GMTs) of Vaccine Antibodies After Vaccination With Either DTaP-Hep B-PRP-T Concomitantly With OPV or Tritanrix-Hep B/Hib™ Concomitantly With OPV | Group 2: Tritanrix-Hep B/ Hib™ + OPV | Anti-Filamentous Hemagglutinin (N = 205, 94) | 9.17 | 95% Confidence Interval 7.33 to 11.5 | Titers |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00348881/results